Email Us
View Reports

Dechra Pharmaceuticals PLC Company Profile - Overview, History, SWOT Analysis, Products/Services, Facts, Financials, Key Executives, Competitors, Tech Intelligence, IT Outsourcing, IT Management, Recent Developments and Strategy Evaluation

  • ID : 4342686  |  
  • Published : Apr-2018  |  
  • Region : Global  |  
  • Pages : 35   |  
  • Publisher : Market Data Forecast

Dechra Pharmaceuticals PLC (Dechra) is a UK-based veterinary pharmaceutical group, engaged in developing, manufacturing, distributing, selling and marketing of animal products to the veterinary industry. The group has operations in Europe and the US. The group operates its business through three reportable segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. Under the European pharmaceuticals business segment, Dechra's includes the operations of Dechra Veterinary Products (DVP) EU, Genera and Dechra pharmaceuticals manufacturing. Dechra pharmaceuticals manufactures a range of branded licensed pharmaceutical products, including pharmaceutical powders, capsules, tablets, liquids, creams, ointments, injections, and gels. It also operates internationally and manufactures and markets Companion Animal, Equineand Food producing Animal Products. Its products are marketed through DVP EU. In FY2017, the European Pharmaceuticals segment reported revenue of GBP226.93 million, which accounted for 63.16% of the company’s total revenue. Under the North American Pharmaceuticals business segment, Dechra's comprises the operations of Dechra Veterinary Products US and Dechra Veterinary Products Canada, which sell companion animal and equine pharmaceuticals. This segment is engaged in marketing and developing Dechra's branded endocrine, ophthalmic, dermatological, equine, analgesia and critical care, cardiovascular, food producing animal products, and pet diet products to the veterinary profession in the US. The group distributes its endocrine products under the brand names, including Vetoryl, Forthyron and Felimazole; dermatology brands, including Canaural, Isaderm, Malaseb, CleanAural and DermaPet; Equipalazone, Osphos, HY-50, Somulose and Domidine for equine; ophthalmic related brands include Isathal, Lubrithal, Vetropolycin and Vetroploycin HC; analgesia and critical care brands include Vetivex, Sedator, Comfortan, Phycox and Atipam; cardiovascular related brand include Cardisure; food producing animal product brands, including Octacillin, Methoxasol, Cyclospray, Rapidexon and Soludox; and pet diet related brand include Specific. In FY2017, the North American Pharmaceuticals segment reported revenue of GBP132.3 million, which accounted for 36.83% of the company’s total revenue. Under the Dechra's pharmaceuticals research and development segment is engaged in developing and licensing the groups branded veterinary product portfolio of pharmaceuticals and pet diets. The group's subsidiaries include the following: Dechra Veterinary Products, Dechra Veterinary Products A/S, Dechra Veterinary Products OY, Dechra Veterinary Products B.V., Dechra Veterinary Products S.L.U., Dechra Veterinary Products AB, Dechra Finance Limited, Dechra Finance Limited AND Eurovet NV. In FY2017, Dechra invested GBP14978 million as compared to GBP10355 million in FY-2016 on research and development activities. Geographically, Dechra classified its operations into five segments: the US, Rest of Europe, the UK, Germany and Rest of the world. In FY2017, the company generated 34.5% of the total revenue from the US, followed by Rest of Europe (31.5%), the UK (15.7%), Germany (10.4%) and Rest of the world (7.9%).

Scope of the Report

-- About the Company - Historical Details, Current Ownership Structure and basic overview of Dechra Pharmaceuticals PLC in terms of revenue, net income, and operating income.

-- Financials - Details about Dechra Pharmaceuticals PLC listing status, annual financial reports (for the past 5 years), key financial highlights and region wise and category wise breakdown of their net revenue.

-- Products / Services - Listing of the company’s entire portfolio along with description of individual products / services providing a clear picture of their target audience.

-- Company SWOT Analysis - Outlines Dechra Pharmaceuticals PLC’s strengths, weaknesses, and opportunities and threats facing the company.

-- Recent Developments - Showcases Dechra Pharmaceuticals PLC’s recent developments including mergers, acquisitions, partnerships, collaborations, new product launches, investment and divestment plans.

-- Strategic Evaluation - Provides an overview of Dechra Pharmaceuticals PLC’s corporate goals and strategic initiatives and evaluates their outcomes along with outlining any persisting legal issues and outlook of our in-house analyst panel on the particular company.

-- Technology Landscape - Details how the company allocates its IT budget across the core areas of its business, CIO/CTO Profile, Key IT Initiatives and Deals undertaken buy the company at present along with outlook.

Key Questions Answered

-- What domain does Dechra Pharmaceuticals PLC operate and what are key points about it?

-- What is the product / service portfolio of Dechra Pharmaceuticals PLC?

-- How has Dechra Pharmaceuticals PLC performed financially from the 2013?

-- How does Dechra Pharmaceuticals PLC rank among its peers in terms of revenue and market share?

-- What are Dechra Pharmaceuticals PLC strengths and weaknesses and what opportunities and threats does it face?

-- What are Dechra Pharmaceuticals PLC’s main growth strategies and how successful has the company been at implementing them?

-- What is the in-house technical capability of Dechra Pharmaceuticals PLC? Where does it procure / outsource it?

Reasons to buy

-- Report delivered in easily accessible PPT format which can be used to gain insights quickly and further prepare presentations of your own

-- Lean pricing structure ultimately giving you vast access to the unlimited knowledge repository of the company profiles at very competitive cost

-- 12 hour delivery time fulfilling your urgent requests as per your requirement

-- On-demand customization options that can completely cater to your needs by focusing the report onto given specifics

1. About the Company

1.1 History and Basic Facts

1.2 Ownership Structure and Key Executives

1.3 Head Office

1.4 Other Locations & Subsidiaries

1.5 List of Competitors

1.6 Employee Count & Distribution

2. Financials

2.1 Company Type (Listed / Unlisted)

2.2 Annual Statements

2.3 Key Financial Highlights

2.4 Region-wise Breakdown

3. Product / Services

3.1 Overview

3.2 Description

4. SWOT Analysis

4.1 SWOT Overview

4.2 Strengths

4.3 Weaknesses

4.4 Opportunities

4.5 Threats

5. Recent Developments

5.1 Mergers & Acquisitions

5.2 Partnerships, Collaborations & Joint Ventures

5.3 New Product Launches

5.4 Business Expansion / Divestment

6. Strategic Evaluation

6.1 Corporate Strategy

6.2 Legal Issues

6.3 Analyst Outlook

7. Technology Landscape

7.1 Industry

-- 7.1.1 Industry Snapshot

-- 7.1.2 IT Spend

-- 7.1.3 Key Information Technology Trends

7.2 Company

-- 7.2.1 IT Overview

-- 7.2.2 Key IT Technologies

-- 7.2.3 Recent IT Initiatives

-- 7.2.4 IT Outsourcing Engagements

-- 7.2.5 Key IT Management

-- 7.2.6 CIO/CTO Profile

Appendix

-- Methodology

-- About Us

-- Contact Us

-- Disclaimer

Fig.1: Company Snapshot

Fig.2: Locations Listing on Map

Table.1: Ownership Structure

Table.2: List of Competitors

Table.3: Annual Statements

Table.4: Key Financial Highlights

Table.5: Region-wise Breakdown

Table.6: Product/Services Overview

Table.7: Mergers & Acquisitions

Table.8: Partnerships, Collaborations & Joint Ventures

Table.9: New Product Launches

Table.10: Business Expansion / Divestment

Table 11: IT Budgets

Table 12: Key IT Management (CIO / CTO)

Table 13: IT Deals undertaken in the past years

Purchase this Market Research Report

REACH OUT TO US

Call us on : +1 888 709 8757

Drop us an email at : info@researchcosmos.com

HAVE A QUESTION?